Results 11 to 20 of about 438,950 (335)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

PTK2 and PTPN11 expression in myelodysplastic syndromes

Clinics, 2013
OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein ...
Mariana Lazarini, Joao Agostinho Machado-Neto, Leticia Frohlich Archangelo, Bruna Fernandes Mendes-Silva, Carolina Louzao Bigarella, Fabiola Traina, Sara Teresinha Olalla Saad   +6 more
doaj   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +4 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

Aging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022
One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen, Meng‐Meng Ji, Peng‐Peng Xu, Wei‐Li Zhao   +3 more
wiley   +1 more source

Ectopic repression of receptor tyrosine kinase–like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial–mesenchymal transition

Tumor Biology, 2017
Receptor tyrosine kinase–like orphan receptor 2 is an enzyme-linked receptor which specifically modulates WNT5A signaling and plays an important role in tumorigenesis, invasion, and metastasis; however, the precise role of receptor tyrosine kinase–like ...
Ying Xu, Yan-Hui Ma, Ying-Xin Pang, Zhe Zhao, Jing-Jing Lu, Hong-Luan Mao, Pei-Shu Liu   +6 more
doaj   +1 more source

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors

Burns & Trauma, 2014
Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome ...
Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen
doaj   +1 more source

Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, Monosiga brevicollis.

PLoS ONE, 2023
Genomic analysis of the unicellular choanoflagellate, Monosiga brevicollis (MB), revealed the remarkable presence of cell signaling and adhesion protein domains that are characteristically associated with metazoans. Strikingly, receptor tyrosine kinases,
Teena Bajaj, John Kuriyan, Christine L Gee   +2 more
doaj   +1 more source

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

Pharmaceuticals, 2010
Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for
Domenico Ribatti
doaj   +1 more source